These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1510 related articles for article (PubMed ID: 32447649)
1. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649 [TBL] [Abstract][Full Text] [Related]
2. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
3. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer. Lee J; Kim DM; Lee A Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200 [TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas. Duverger L; Osio A; Cribier B; Mortier L; De Masson A; Basset-Seguin N; Lebbé C; Battistella M Cancer Immunol Immunother; 2019 Jun; 68(6):951-960. PubMed ID: 30953116 [TBL] [Abstract][Full Text] [Related]
6. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. Okabe M; Toh U; Iwakuma N; Saku S; Akashi M; Kimitsuki Y; Seki N; Kawahara A; Ogo E; Itoh K; Akagi Y Cancer Sci; 2017 Jan; 108(1):81-90. PubMed ID: 27801993 [TBL] [Abstract][Full Text] [Related]
7. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363 [TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208 [TBL] [Abstract][Full Text] [Related]
9. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. Zhang L; Wang XI; Ding J; Sun Q; Zhang S Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176 [TBL] [Abstract][Full Text] [Related]
10. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553 [TBL] [Abstract][Full Text] [Related]
11. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569 [No Abstract] [Full Text] [Related]
12. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889 [TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of the Tumor-Infiltrating CD8 Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B Front Immunol; 2021; 12():734956. PubMed ID: 34603316 [TBL] [Abstract][Full Text] [Related]
14. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma. Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156 [TBL] [Abstract][Full Text] [Related]
15. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas. Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984 [TBL] [Abstract][Full Text] [Related]
17. The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas. Škuciová V; Drahošová S; Výbohová D; Cígerová V; Adamkov M Pathol Res Pract; 2020 Sep; 216(9):153071. PubMed ID: 32825944 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013 [TBL] [Abstract][Full Text] [Related]
19. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma. Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334 [TBL] [Abstract][Full Text] [Related]
20. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4 Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]